troglitazone has been researched along with Adenocarcinoma in 13 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Adenocarcinoma: A malignant epithelial tumor with a glandular organization.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We compared the effects of six types of TZDs (troglitazone, RS-1303, RS-1330, RS-1387, RS-1455, and RS-1456) and 9-cis RA, an RXRalpha ligand, on the activation of PPARgamma/RXRalpha and the growth inhibition of six types of adenocarcinoma cell lines (MKN45, HT-29, HCT116, HuCCT1, KMP-2, and BxPC3) established from abdominal malignancies." | 3.72 | Thiazolidinediones inhibit growth of gastrointestinal, biliary, and pancreatic adenocarcinoma cells through activation of the peroxisome proliferator-activated receptor gamma/retinoid X receptor alpha pathway. ( Dono, K; Hayashi, N; Hiraoka, N; Monden, M; Nagano, H; Nakamori, S; Okami, J; Sakon, M; Tsujie, M; Umeshita, K, 2003) |
| "Troglitazone was a widely used antidiabetic drug that activates PPARgamma." | 1.31 | Down-Regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor gamma in human prostate cancer. ( Carey, M; Hisatake, JI; Holden, S; Ikezoe, T; Koeffler, HP; Tomoyasu, S, 2000) |
| "Troglitazone showed a potent dose-response effect on the growth inhibition of six pancreatic cancer cell lines, which were suppressed to less than 50% of control at the concentration of 10 microM." | 1.31 | Growth inhibition and differentiation of pancreatic cancer cell lines by PPAR gamma ligand troglitazone. ( Kawa, S; Kiyosawa, K; Nakayama, K; Nikaido, T; Unno, H; Usuda, N, 2002) |
| "The development of colorectal cancer, one of the most frequent cancers, is influenced by prostaglandins and fatty acids." | 1.30 | Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. ( Auwerx, J; Briggs, M; Chen, I; Desreumaux, P; Fruchart, JC; Geboes, K; Heyman, R; Lefebvre, AM; Najib, J, 1998) |
| "Ligand activation of this receptor in colon cancer cells causes a considerable reduction in linear and clonogenic growth, increased expression of carcinoembryonic antigen and the reversal of many gene expression events specifically associated with colon cancer." | 1.30 | Differentiation and reversal of malignant changes in colon cancer through PPARgamma. ( Chen, LB; DeAngelo, DJ; Fletcher, C; Holden, SA; Jones, D; King, FJ; Mueller, E; Partridge, JB; Sarraf, P; Singer, S; Spiegelman, BM, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (30.77) | 18.2507 |
| 2000's | 8 (61.54) | 29.6817 |
| 2010's | 1 (7.69) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fröhlich, E | 1 |
| Wahl, R | 1 |
| Gras, D | 1 |
| Chanez, P | 1 |
| Urbach, V | 1 |
| Vachier, I | 1 |
| Godard, P | 1 |
| Bonnans, C | 1 |
| Surazynski, A | 1 |
| Jarzabek, K | 1 |
| Miltyk, W | 1 |
| Wolczynski, S | 1 |
| Palka, J | 1 |
| Burgermeister, E | 1 |
| Tencer, L | 1 |
| Liscovitch, M | 1 |
| Tsujie, M | 1 |
| Nakamori, S | 1 |
| Okami, J | 1 |
| Hayashi, N | 1 |
| Hiraoka, N | 1 |
| Nagano, H | 1 |
| Dono, K | 1 |
| Umeshita, K | 1 |
| Sakon, M | 1 |
| Monden, M | 1 |
| Elstner, E | 1 |
| Müller, C | 1 |
| Koshizuka, K | 1 |
| Williamson, EA | 1 |
| Park, D | 1 |
| Asou, H | 1 |
| Shintaku, P | 1 |
| Said, JW | 1 |
| Heber, D | 1 |
| Koeffler, HP | 2 |
| Lefebvre, AM | 1 |
| Chen, I | 1 |
| Desreumaux, P | 1 |
| Najib, J | 1 |
| Fruchart, JC | 1 |
| Geboes, K | 1 |
| Briggs, M | 1 |
| Heyman, R | 1 |
| Auwerx, J | 1 |
| Sarraf, P | 1 |
| Mueller, E | 1 |
| Jones, D | 1 |
| King, FJ | 1 |
| DeAngelo, DJ | 1 |
| Partridge, JB | 1 |
| Holden, SA | 1 |
| Chen, LB | 1 |
| Singer, S | 1 |
| Fletcher, C | 1 |
| Spiegelman, BM | 1 |
| Saez, E | 1 |
| Tontonoz, P | 1 |
| Nelson, MC | 1 |
| Alvarez, JG | 1 |
| Ming, UT | 1 |
| Baird, SM | 1 |
| Thomazy, VA | 1 |
| Evans, RM | 1 |
| Hisatake, JI | 1 |
| Ikezoe, T | 1 |
| Carey, M | 1 |
| Holden, S | 1 |
| Tomoyasu, S | 1 |
| Motomura, W | 1 |
| Okumura, T | 1 |
| Takahashi, N | 1 |
| Obara, T | 1 |
| Kohgo, Y | 1 |
| Takashima, T | 1 |
| Fujiwara, Y | 1 |
| Higuchi, K | 1 |
| Arakawa, T | 1 |
| Yano, Y | 1 |
| Hasuma, T | 1 |
| Otani, S | 1 |
| Kawa, S | 1 |
| Nikaido, T | 1 |
| Unno, H | 1 |
| Usuda, N | 1 |
| Nakayama, K | 1 |
| Kiyosawa, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pilot Trial of Pioglitazone in Adults Undergoing Surgical Resection of Non-Small Cell Lung Cancer[NCT00923949] | Phase 2 | 1 participants (Actual) | Interventional | 2008-08-31 | Terminated (stopped due to Study never published; terminated early due to low accrual.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Here are the number of participants with adverse events. For details about the adverse events see the adverse event module. (NCT00923949)
Timeframe: 58 days
| Intervention | Participants (Number) |
|---|---|
| Pioglitazone | 1 |
1 review available for troglitazone and Adenocarcinoma
| Article | Year |
|---|---|
The current role of targeted therapies to induce radioiodine uptake in thyroid cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Chromans; Female; Forecasting; Gene Expression Regulation, Ne | 2014 |
12 other studies available for troglitazone and Adenocarcinoma
| Article | Year |
|---|---|
Thiazolidinediones induce proliferation of human bronchial epithelial cells through the GPR40 receptor.
Topics: Adenocarcinoma; Anilides; Bronchi; Calcium Signaling; Cell Division; Cell Line, Transformed; Cell Li | 2009 |
Estrogen-dependent regulation of PPAR-gamma signaling on collagen biosynthesis in adenocarcinoma endometrial cells.
Topics: Adenocarcinoma; Cell Line, Tumor; Chromans; Collagen; Endometrial Neoplasms; Estrogens; Female; Huma | 2009 |
Peroxisome proliferator-activated receptor-gamma upregulates caveolin-1 and caveolin-2 expression in human carcinoma cells.
Topics: Adenocarcinoma; Antigens, Differentiation; Antigens, Neoplasm; Breast Neoplasms; Caveolin 1; Caveoli | 2003 |
Thiazolidinediones inhibit growth of gastrointestinal, biliary, and pancreatic adenocarcinoma cells through activation of the peroxisome proliferator-activated receptor gamma/retinoid X receptor alpha pathway.
Topics: Adenocarcinoma; Alitretinoin; Antineoplastic Agents; Apoptosis; Biliary Tract Neoplasms; Cell Differ | 2003 |
Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice.
Topics: Adenocarcinoma; Animals; Apoptosis; Breast; Breast Neoplasms; Cell Differentiation; Chromans; Genes, | 1998 |
Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice.
Topics: Adenocarcinoma; Animals; beta Catenin; Chromans; Colorectal Neoplasms; Cyclooxygenase 2; Cytoskeleta | 1998 |
Differentiation and reversal of malignant changes in colon cancer through PPARgamma.
Topics: Adenocarcinoma; Animals; Cell Differentiation; Cell Division; Chromans; Colonic Neoplasms; Gene Expr | 1998 |
Activators of the nuclear receptor PPARgamma enhance colon polyp formation.
Topics: Adenocarcinoma; Adenomatous Polyposis Coli; Animals; Chromans; Diet; Humans; Ligands; Mice; Mice, In | 1998 |
Down-Regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor gamma in human prostate cancer.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents; Blotting, Western; Chromans; Dihydrotes | 2000 |
Activation of peroxisome proliferator-activated receptor gamma by troglitazone inhibits cell growth through the increase of p27KiP1 in human. Pancreatic carcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Blotting, Northern; Cell Cycle Proteins; Cell Division; Chrom | 2000 |
PPAR-gamma ligands inhibit growth of human esophageal adenocarcinoma cells through induction of apoptosis, cell cycle arrest and reduction of ornithine decarboxylase activity.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell | 2001 |
Growth inhibition and differentiation of pancreatic cancer cell lines by PPAR gamma ligand troglitazone.
Topics: Adenocarcinoma; Cell Differentiation; Cell Division; Chromans; Dose-Response Relationship, Drug; Flo | 2002 |